Mechanisms of angiotensin converting enzyme inhibitor-induced IOP reduction in normotensive rats

Eur J Pharmacol. 2014 May 5:730:8-13. doi: 10.1016/j.ejphar.2014.02.021. Epub 2014 Feb 26.

Abstract

Angiotensin converting enzyme inhibitors (ACEIs) have been shown to lower intraocular pressure (IOP). Since, the ACEIs cause increased tissue prostaglandin levels, we hypothesized that the mechanisms of ACEI-induced IOP reduction have similarity with those of prostaglandin analogs. The present study investigated the involvement of matrix metalloproteinases (MMPs) and cytokine activity modulation as the underlying mechanisms of ACEI-induced ocular hypotension. The IOP lowering effect of single drop of enalaprilat dehydrate 1% was evaluated in rats pretreated with a broad spectrum MMP inhibitor or a cytokine inhibitor. Effect of angiotensin receptor blocker, losartan potassium 2%, was also studied to evaluate involvement of angiotensin II receptor type 1 (AT1) in IOP lowering effect of ACEI. Topical treatment with single drop of enalaprilat resulted in significant IOP reduction in treated eye with mean peak reduction 20.3% at 3h post-instillation. Treatment with losartan resulted in a peak IOP reduction of 13.3%, which was significantly lower than enalaprilat, indicating involvement of mechanisms in addition to AT1 blockade. Pretreatment with a broad spectrum MMP inhibitor or a cytokine inhibitor significantly attenuated the enalprilat-induced IOP reduction with mean peak IOP reduction of 11.2% and 13.6% respectively. The IOP-lowering effect of enalaprilat seems to be attributed to reduced angiotensin II type 1 receptor stimulation and modulation of MMP and cytokines activities.

Keywords: Angiotensin II type 1 receptor blocker; Angiotensin converting enzyme inhibitor; Enalaprilat; Intraocular pressure; Matrix metalloproteinase; Tumor necrosis factor-alpha.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / administration & dosage
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Animals
  • Aqueous Humor / drug effects
  • Aqueous Humor / metabolism
  • Dinoprost / metabolism
  • Intraocular Pressure / drug effects*
  • Male
  • Matrix Metalloproteinases / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Tumor Necrosis Factor-alpha
  • Dinoprost
  • Matrix Metalloproteinases